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Abstract: Dexmedetomidine is a commonly used sedative and adju-
vant agent to general anesthesia. The present was designed to evaluate
the effects of dexmedetomidine on myocardial function by using tissue
Doppler echocardiography during general anesthesia in patients with
diastolic dysfunction.
Forty patients undergoing orthostatic surgery with ejection fraction
preserveddiastolic dysfunction grade 2 or 3were randomlyallocated to the
Control andDexgroup (n¼ 20, each). In theDexgroup, dexmedetomidine
was given as an initial loading dose of 1.0mg/kg over 10minutes followed
by a maintenance dose of 0.5mg/kg/h. The ratio of peak early diastolic
transmitral or transtricuspid inflow velocity to early diastolic mitral or
tricuspid annular velocity (LV or RV E/e0) and left or right ventricular
myocardial performance index (LV or RVMPI) were measured at before
and after the administration dexmedetomidine or saline.
The Dex group showed significant decrease of heart rate (P¼ 0.038),
and increase of mean blood pressure (P< 0.001), LV E/e0 (P¼ 0.025),
and LV MPI (P< 0.001) compared to those of the Control group on a
linear mixed model analysis. Also, the Dex group showed significant
increase of RV E/e0 (P< 0.001) and RV MPI (P¼ 0.028) compared to
those of the Control group.
Intraoperative dexmedetomidine administration during general
anesthesia was appeared to deteriorate biventricular function in patients
with diastolic dysfunction. We suggest careful consideration and a need
for reducing dosage when administrating dexmedetomidine in patients
with diastolic dysfunction., Namo Kim, MD MD,
ung Jun Oh, MD, PhD
heart rate, LV = left ventricle, MBP = mean blood pressure, MPI =
myocardial performance index, MV e0 = peak early diastolic mitral
annular velocity, MV s0 = peak systolic mitral annular velocity, RV
= right ventricle, TAPSE = tricuspid annular plane systolic
excursion, TV E = peak early diastolic transtricuspid inflow
velocity, TVe0 = peak early diastolic tricuspid annular velocity, TV
s0 = peak systolic tricuspid annular velocity.
INTRODUCTION
D exmedetomidine is a highly selective a2-adrenoreceptoragonist that has gained popularity in the intensive care
unit, cardiovascular intervention1 and endoscopic procedures,
and as an adjuvant to general anesthesia2 for its sedative and
analgesic effects. Although there have been studies suggesting
the use of perioperative dexmedetomidine in cardiac surgery
improved postoperative morbidity and mortality,3,4 there is also
conflict in literature that have reported adverse cardiovascular
effects of dexmedetomidine including hypotension or hyper-
tension, bradycardia, and even cardiac arrest.5,6 Even with the
amounting evidence that dexmedetomidine has critical cardio-
vascular effects, few studies have investigated the direct effects
of dexmedetomidine on cardiac function. Although our
previous study7 presented evidence that dexmedetomidine
administration had minimal effects on cardiac function in
young healthy patients, there are no current studies assessing
the effects of dexmedetomidine administration on biventricular
function in patients with cardiac dysfunction. In a recent study,8
64.1% of patients over 65 years were assessed with diastolic
dysfunction. Regardless, the importance of diastolic dysfunc-
tion has been underestimated in comparison to systolic dysfunc-
tion. Because preoperative diastolic dysfunction is highly
affiliated with overall postoperative prognosis,9 mortality after
acute coronary syndrome,10 and adverse postoperative outcome
of patients with myocardial infarction,11 undermining diastolic
dysfunction may be a critical mistake. As dexmedetomidine
becomes a more ubiquitous agent in the clinical field, we
believe a true evaluation of dexmedetomidine on cardiac func-
tion in patients with cardiac dysfunction is critically essential.
Tissue Doppler indices are more reliable in estimating
cardiac function than 2-dimensional or conventional Doppler
echocardiography in patients with preexisting left ventricle (LV)
relaxation impairment. The ratio (E/e0) of peak early diastolic
transvalvular inflow velocity (E) to early diastolic valvular
annular velocity (e0) is a valuable tool in diagnosing diastolic
dysfunction independent of preload, in patients with preservedF) and impaired LV relaxation.12 Tissue
ed myocardial performance index (MPI),
ystolic and diastolic performance to
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evaluate global cardiac function.13 Its most prominent use is to
assess diastolic function. In contrast to Doppler-assessed trans-
valvular blood flow, tissue Doppler imaging derived MPI is
relatively independent of heart rate (HR)14 and loading con-
ditions.15
In this randomized, double-blind, and placebo-controlled
trial, we investigated the effects of dexmedetomidine on myo-
cardial function in patients with diastolic dysfunction by using
tissue Doppler imaging derived indices including MPI and E/e0
during general anesthesia.
METHODS
Study Population
This study received approval from the institutional review
board of Severance Hospital, Yonsei University Health System,
Seoul, South Korea (Ref. 4-2015-0284) on May 2015 and was
registered at Clinical Trials.gov (NCT02490072). All partici-
pants provided written informed consent before participation.
Patients undergoing orthopedic surgery in supine position were
included. The inclusion criteria were American Society of
Anesthesiologists physical status of class II or III, over 40
years of age, and patients with sinus rhythm lateral mitral
valvular (MV) e’ velocity < 10 cm/s or septal MV e’ velocity
< 8 cm/s and averaged LV E/e0 9 on preoperative transthoracic
echocardiographic evaluation. Averaged LV E/e0 ¼ 9–12 was
defined as diastolic dysfunction grade 2, and LV E/e0 13 was
defined at diastolic dysfunction grade 3.16 The patients with
LV systolic function preserved (LV EF 50%) diastolic dys-
function were enrolled in this study. For patients without
preoperative echocardiographic examination, we performed a
transthoracic echocardiography prior to surgery. The patients
with lateral MV e0 velocity <10 cm/s or septal MV e0 velocity
<8 cm/s were enrolled in our study (Figure 1). The exclusion
criteria were the patients with severe functional liver or kidney
disease, diagnosed heart failure, regional wall motion abnorm-
ality of LV, history of arrhythmia or treatment with antiarrhyth-
mic drugs, bradycardia (HR <45 beats/min) or atrioventricular
Lee et alblock, and severe chronic obstructive lung disease. Enrolled
patients were randomly allocated to the Control or dexmede-
tomidine group (Dex group) using a randomized sequence
FIGURE 1. Algorism used for diastolic dysfunction grading.
LV¼ left ventricle, MV e0 ¼peak early diastolic mitral annular
velocity, MV E¼peak early diastolic transmitral inflow velocity.
2 | www.md-journal.comgenerated by a computer, and the randomization process was
centralized. A concealed envelope for random allocation was
sent to anesthesia nurses who prepared the dexmedetomidine or
saline of comparable volume. Therefore, the anesthesiologist
infused the drug in a blind manner. The participating anesthe-
siologists, nurses, surgeons, and patients were blinded to the
treatment allocation.
Anesthetic Management
After each patient arrived to the operating room, normal
saline 5mL/kg was administrated to replace the fluid deficit.
Patients were not premedicated. Blood pressure, oxygen satur-
ation, electrocardiography, and bispectral index (BIS; A-200
bispectral index monitor, Aspect Medical System Inc., Newton,
MA) were monitored noninvasively. Anesthesia was induced by
propofol and remifentanil through a target-controlled infusion
system (Orchestra; Base Primera, Fresenius Vial, Brezins,
France). Following the loss of consciousness, rocuronium
0.8mg/kg was administered to facilitate tracheal intubation.
During the surgery, the dose of propofol and remifentanil were
adjusted to maintain BIS range between 40 and 50 in both
groups. The effect site concentration and total dose of each
administered propofol and remifentanil were recorded. Hemo-
dynamic instability was treated as follows: atropine was admi-
nistered when the HR decreased to <45 beats/min, while b1-
adrenergic antagonist was administered when HR increased to
120 beats/min. When mean blood pressure (MBP) decreased
to below 20% of baseline value, phenylephrine (50mg) was
administered. When MBP increased up to 120mmHg, calcium
channel blocker (500mg) was administered. In cases of vaso-
active drug administration, measurement was not performed
within 5minutes to minimize its influence on the echocardio-
graphic evaluation.
Intervention
Dexmedetomidine (Precedex; Hospira, Lake Forest, IL)
200mg was added with normal saline to achieve a total volume
of 50mL. Dexmedetomidine was started once the patient was
hemodynamically stable after the induction of anesthesia: a
bolus of 1.0mg/kg over 10minutes followed by a continuous
Medicine  Volume 95, Number 6, February 2016infusion at 0.5mg/kg/h infusion for 1 hour in Dex group. A
comparable volume of normal saline was administered in
the Control.
Echocardiographic Measurements
The blinded anesthesiologist inserted a 4–7MHz multi-
plane transoesophageal echocardiography (TEE) probe (6TC;
GE, Vingmed Ultrasound AS, Horten, Norway) via the oeso-
phagus and connected it to a cardiac ultrasound system (Vivid
E9; GE, Vingmed Ultrasound AS, Horten, Norway). The
echocardiographic examination was performed by the same
anesthesiologist. To assess LVand right ventricle (RV) diastolic
function, pulsed-wave Doppler ultrasonography was used to
measure transmitral and transtricuspid flow at mid-oesopha-
geal 4-chamber views. The peak early diastolic transmitral
inflow velocity (MV E), peak early diastolic (MV e0), and
systolic (MV s0) mitral annular velocity were measured at the
lateral and septal annular by tissue Doppler imaging. Average
LVE/e0was obtained by averaging the total of lateral and septal
LV E/e0. Peak early diastolic (TV e0) and systolic (TV s0)
tricuspid annular velocity were also measured at lateral tri-
cuspid annular. The ratio (RV E/e0) of peak early diastolic
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
pared to the Control group after 20 and 40minutes. Also, the
TABLE 1. Inter- and Intra-observer Variability
Intra-observer
Variability
Inter-observer
Variability
MV e0 1.8 (1.2–2.5) 2.1 (1.1–2.8)
EF 6.4 (2.6–7.8) 6.0 (3.4–8.2)
LV FAC 2.3 (1.7–2.9) 2.2 (1.4–2.8)
LV MPI 1.3 (0.7–2.3) 1.5 (0.8–2.2)
MV s0 1.7 (1.3–2.4) 2.3 (1.4–3.1)
TV e0 2.0 (1.2–2.8) 2.6 (1.8–3.5)
TAPSE 6.0 (3.8–8.2) 6.1 (4.6–8.6)
TV s0 2.0 (1.4–2.7) 2.2 (1.3–2.9)
RV MPI 1.5 (1.0–2.3) 1.7 (1.2–2.5)
Values are expressed as percentages (95% confidence intervals).
EF¼ ejection fraction, FAC¼ fractional area change, LV MPI¼ left
ventricular myocardial performance index, MV e0 ¼ peak early diastolic
mitral annular velocity, MV s0 ¼ peak systolic mitral annular velocity,
RV MPI¼ right ventricular myocardial performance index, TAP-
SE¼ tricuspid annular plane systolic excursion, TV e0 ¼ peak early
diastolic tricuspid annular velocity, TV s0 ¼ peak systolic tricuspid
Dexmedetomidine and Diastolic Functiontranstricuspid inflow velocity (TV E) to TV e0 was acquired
from these data. LV and RV MPI was defined as follows:
(isovolumic contraction timeþ isovolumic relaxation time)/
ejection time. The normal reference value of LV and RV MPI
are considered 0.39 0.0517 and 0.28 0.04.18 To assess LV
systolic function and dimension, LVend-diastolic area, LVend-
systolic area, and EFweremeasured from themid-oesophageal
4-chamber view. Fractional area change (FAC) was calculated
in the mid-oesophageal 4-chamber view using the following
formula: FAC¼ ([end-diastolic area end-systolic area]/end-
diastolic area) 100. RV systolic function was assessed by
tricuspid annular plane systolic excursion (TAPSE).19 Cardiac
output was assessed by stroke volume using pulsed-wave
Doppler measurements from the LVoutflow tract. The cardiac
output was calculated: Cardiac output¼ stroke volumeHR.
All variables were means of the values measured over 3 cardiac
cycles during end-expiration. Analysis of the echocardio-
graphic data was performed by 1 anesthesiologist who was
blinded to the group assignments. To determine intra- and
interobserver variability, a random sample of 25% of all
echocardiographic data was submitted twice to a 1st investi-
gator and once to a 2nd investigator. The variabilities were
calculated as the mean absolute differences between the 2
readings divided by their mean and expressed as a percentage
and their 95% confidence intervals (Table 1). The concen-
tration of propofol and remifentanil, MBP, HR, BIS, and TEE
examination were measured after the patient became hemo-
dynamically stable for 10minutes after induction and before, at
20, 40, and 60minutes after the administration dexmedetomi-
dine or saline.
Statistical Analysis
For justification of numbers, the primary outcome measure
was defined as the LV E/e0. A difference of 3.0 between the
Control and Dex group was taken as clinically significant in the
preliminary results for the 1st 10 patients. Previously, our
studies7 have also found a standard deviation (SD) of 3.2 for
dexmedetomidine administered group. With a¼ 0.05 and
power of 0.8 at least 18 patients were needed in each group.
Assuming a dropout rate of 10%, 20 patients for each group, 40
patients in total were included in this study. Results are
expressed as meanSD or numbers (proportion). Unpaired
Student t-test was used for continuous variables, and Chi-
squared or Fisher’s exact test was used for categorized variables
between 2 groups. The analysis of repeated variables were
performed by a linear mixed model for random and fixed effects
between the 2 groups. Post hoc analyses with the Bonferroni
correction were performed for multiple comparisons when
variables with repeated measures showed significant differences
between groups. The statistical analyses were performed with
SPSS 20.0 software (SPSS Inc., Chicago, IL) and P values less
than 0.05 were considered statistically significant.
RESULTS
A total of 48 patients were assigned for eligibility. Dias-
tolic dysfunction was confirmed by preoperative echocardio-
graphy in 32 patients and transthoracic echocardiography in 16
patients. Six patients did not meet the inclusion criteria, and 2
patients refused participation in this study. Therefore, each
group included 20 randomly assigned patients and a total of
Medicine  Volume 95, Number 6, February 201640 patients were enrolled in this study (Figure 2). There were no
significant demographic characteristic differences between the
2 groups (Table 2). The administration of vasoactive drugs
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.during surgery was more frequent in the Dex group, but not
significant different between the 2 groups. In the Dex group, the
total administered dose of propofol was significantly decreased,
while that of remifentanil was not different between the
2 groups.
As shown in Table 3, significant differences in MBP, HR,
BIS, and effect site concentration of propofol were found
between the 2 groups using linear mixed model analyses
(P< 0.001, P¼ 0.038, P¼ 0.027, and P¼ 0.022, respectively).
MBP of the Dex group was significantly higher than that of the
Control group (P< 0.01, respectively), while HR was lower in
the Dex group than that of the Control group after 20, 40, and
60minutes (P< 0.01, respectively).
The Dex group showed a significant increase of LV and
RV MPI (P< 0.001 and P¼ 0.028, respectively; Figure 3 and
Table 4). As shown in Table 4, the Dex group presented a
significant increase of LV E/e0 (P¼ 0.025), and a significant
decrease of MV e0, MV s0, EF, FAC, and cardiac output
compared to the Control group (P¼ 0.039, P¼ 0.003,
P¼ 0.015, P< 0.001, and P< 0.001, respectively). The Dex
group presented a significant increase in RV E/e0 (P< 0.01),
and a significant decrease of TV e0, TV s0, and TAPSE
(P¼ 0.047, P¼ 0.041, and P< 0.01, respectively). There was
a significant increase of RV E/e0 and a decrease of TV e0 in the
Dex group compared to the Control group after 20 and 40min-
utes. RV MPI of the Dex group significantly increased com-
annular velocity.Dex group presented decreased TV s0 and TAPSE when com-
pared to the Control group after 20 and 40minutes.
DISCUSSION
In this study, the administration of dexmedetomidine to the
patients with preexisting diastolic dysfunction resulted in a
decrease of HR and increase of MBP, MPI, and E/e0 during
general anesthesia. Therefore, dexmedetomidine administration
during general anesthesia deteriorated biventricular function in
patients with underlying diastolic dysfunction.
www.md-journal.com | 3
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Lee et al Medicine  Volume 95, Number 6, February 2016E/e0 is a relatively load-independent indicator used to
estimate LV filling pressure in patients with EF preserved
diastolic dysfunction.12 MPI is a comprehensive way to evalu-
ate systolic and diastolic cardiac function within 1 cardiac
cycle.17 In our results, the baseline MPI was prolonged, and
dexmedetomidine further augmented biventricular MPI pro-
longation. Also, LV EF, and MV s0 significantly decreased
in the Dex group. In patients with EF preserved diastolic
dysfunction, dexmedetomidine significantly depressed systolic
function as well as diastolic function. Accordingly, when
administering dexmedetomidine to patients with diastolic dys-
function, we propose the need to adjust drug dosage and further
study is needed to evaluate the relationship between decreased
dosage of dexmedetomidine and cardiac function. In our
previous study7 of healthy young patients without cardiac
dysfunction, transient blood pressure elevation occurred only
directly after dose loading of dexmedetomidine. Moreover, the
transient increase of blood pressure after loading dexmedeto-
midine did not affect biventricular diastolic and systolic func-
tion. In comparison, in our current study on patients with
diastolic dysfunction, the increase of blood pressure persisted
throughout the entire dexmedetomidine administration. With
this sort of hemodynamic change, dexmedetomidine could
induce a rise of LV afterload and have effects on LV relaxation
and filling in patients with diastolic dysfunction, which is
evidenced by the decrease of e0 and increase of E/e0. These
FIGURE 2. CONSORT flow chart. e0 ¼peak early diastolic mitral aresults can be explained by the physiology of diastolic dysfunc-
tion. In a diastolic impaired heart, the increased afterload delays
onset of relaxation and increases isovolumic relaxation time.20
4 | www.md-journal.comAlthough a normal heart is able to react to elevated afterload
without change in LV end-systolic volume,21 a heart with
decreased afterload reservoir shows marked deterioration of
LV relaxation in response to even a slight increase of afterload,
thus resulting in an increase of LV systolic and diastolic
volume.22
Interestingly, this study revealed that most patients with
LV diastolic dysfunction also accompanied RV systolic and
diastolic dysfunction. In patients with LV diastolic dysfunc-
tion, decreased TV e0 (7.1 1.3 at baseline; normal value,
14.5 3.5)23 represents a depressed RV diastolic function.
Because RV is a thin-walled and retrosternal structure, it is
difficult to completely visualize RV in a single echocardio-
graphic view. The parameters derived from tissue Doppler
imaging are valuable in estimating RV function,24 especially
RV MPI can be considered to have powerful prognostic
value.25 RV diastolic dysfunction is due to ventricular inter-
dependence as the geometric shape of 1 ventricle directly
affects the contralateral ventricle through the septum.26 Elev-
ated LV end-diastolic pressure in patients with chronic LV
diastolic dysfunction causes pulmonary venous hypertension
and the raised pulmonary vascular resistance causes pulmon-
ary artery hypertension. Pulmonary artery hypertension
evokes a rise in RV afterload and subsequently results in
RV systolic failure.27 Unfortunately, our study was clinically
based, thus we could not evaluate pulmonary artery pressure.
lar velocity.Therefore, we were unable to confirm this systematic mech-
anism of impaired RV function after dexmedetomidine
administration.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Baseline Demographic and Clinical Characteristics
Dex (n¼ 20) Control (n¼ 20) P
Age, y 70.5 6.0 71.0 5.5 0.684
Sex (male/female) 9 (45.0)/11 (55.0) 9 (45.0)/11 (55.0) > 0.99
Body mass index, kg/m2 23.5 3.4 24.4 2.7 0.736
ASA classification II/III 11 (55.0)/9 (45.0) 10 (50.0)/10 (50.0) 0.751
Grade of diastolic dysfunction 2/3 10 (50.0)/10 (50.0) 10 (50.0)/10 (50.0) > 0.99
Hypertension, n 11 8 0.34
RAAS inhibitor 7 6 0.73
Calcium channel blocker 5 1 0.076
b-adrenergic antagonists 2 0 0.147
Furosemide 3 2 0.632
Diabetes mellitus, n 4 2 0.375
Intraoperative data
Number of receiving nicardipine, n 6 2 0.113
Number of receiving ephedrine, n 3 1 0.291
Number of receiving atropine, n 3 0 0.341
Total administrated dose of propofol during study, mg 407.5 68.6 508.0 73.0 < 0.001
Total administrated dose of remifentanil during study, mg 437.5 76.9 412.0 115.6 0.741
Total administrated dose of dexmedetomidine, mg 97.2 16.1 –
Anesthesia time, minutes 132.1 22.3 129.8 31.4 0.082
Operation time, minutes 107.9 23.6 113.8 41.2 0.064
Intake fluid, mL 630.4 36.7 642.7 40.2 0.314
Urine output, mL 100.9 22.3 97.6 31.9 0.216
Estimated blood loss, mL 44.7 23.6 57.2 18.6 0.062
Type of surgery, n
Total knee replacement 4 3 > 0.99
Total hip replacement 6 2 0.432
Open or closed reduction and internal fixation of femur 3 5 0.695
Open or closed reduction and internal fixation of upper limb 5 6 > 0.99
Open or closed reduction and internal fixation of lower limb 2 4 0.661
Data are presented as the meanSD, or number (percentage). ASA¼American Society of Anesthesiologists, RAAS¼ renin-angiotensin-
aldosteron system.
P< 0.001 compared with Control group.
TABLE 3. Effect Site Concentration of Anesthetics, Hemodynamics, and BIS Score
Baseline 20 minutes 40 minutes 60minutes Pgrouptime
Propofol conc., mg/mL 0.022
Dex 3.4 0.7 2.0 0.3, 1.9 0.3, 2.0 0.3,
Control 3.5 0.5 3.2 0.4 3.3 0.4 3.0 0.3
Remifentanil conc., mg/mL 0.785
Dex 2.8 0.9 3.2 0.7 3.2 0.6 3.2 0.6
Control 2.7 0.6 3.1 1.0 3.1 0.7 3.0 0.6
MBP, mm Hg < 0.001
Dex 78.6 10.6 93.0 12.3, 89.5 12.3, 90.0 11.9,
Control 77.2 14.1 80.4 13.6 79.0 7.9 77.2 10.0
HR, beats/min 0.038
Dex 75.8 11.5 61.8 9.1, 56.4 10.4, 59.7 8.9,
Control 71.8 9.7 72.2 12.6 72.2 11.3 71.0 10.4
BIS 0.027
Dex 44.8 4.6 41.6 3.9, 40.8 2.4, 41.4 2.1,
Control 45.6 5.5 46.1 5.6 47.5 7.1 45.8 6.7
Data are expressed as meanSD. 20¼ 20minutes after dexmedetomidine administration, 40¼ 40minutes after dexmedetomidine administration,
60¼ 60minutes after dexmedetomidine administration, Baseline¼ before administration of dexmedetomidine, BIS¼ bispectral index, Con-
trol¼ control group, DEX¼ dexmedetomidine group, HR¼ heart rate, MBP¼mean blood pressure, Propofol conc.¼ effect site concentration of
propofol, Remifentanil conc.¼ effect site concentration of remifentanil.
P< 0.05 compared with Control group.
P< 0.01 compared with Control group.
P< 0.05 compared with Baseline.
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FIGURE 3. Biventricular function. (A) LVMPI, (B) RVMPI, (C) LV E/e0, and (D) RV E/e0. Data aremeanwith error bars showing SD. Baseline,
before administration of dexmedetomidine; 20minutes, 20minutes after dexmedetomidine administration; 40minutes, 40minutes after
dexmedetomidine administration; 60minutes, 60minutes after dexmedetomidine administration.

P<0.05 compared with Control
group, yP<0.01 compared with Control group, and zP<0.05 compared with Baseline. LV E/e0 ¼ the ratio of peak early diastolic
transmitral inflow velocity to early diastolic mitral annular velocity, LV MPI¼ left ventricular myocardial performance index, RV E/e0 ¼ the
sto
Lee et al Medicine  Volume 95, Number 6, February 2016Another interesting findings made through this study was
that the Dex group presented more cases of increased MBP
requiring nicardipine administration compared to the Control. It
is known that the initial transient increase of blood pressure
induced by dexmedetomidine mainly involves vasoconstriction
due to vascular smooth muscle contraction by the activation of
peripheral a2B-adrenoreceptors.
28 This contraction state of the
vascular smooth muscles is regulated by Ca2þ-dependent29 or
Ca2þ-sensitization mechanism.30 The vasodilation induced by
dexmedetomidine is due to the action of endothelial nitric oxide
synthase (eNOS) within the vascular endothelium, and the
vasodilation negates the initial vasoconstriction during dexme-
detomidine administration.31 However, in patients with dias-
tolic dysfunction, there is a deficit of NO production or action.32
A recent experimental study revealed a deficit in eNOS is
largely related to diastolic dysfunction.33 Thus, while the
responses to dexmedetomidine of the endothelial components
of the blood vessels are suppressed, the response of Ca2þ-
dependent peripheral vasoconstriction is sustained during dex-
medetomidine administration. In literature, there were conflicts
of results in changes of blood pressure due to dexmedetomidine
administration. In a meta-analysis of randomized, controlled
trials of dexmedetomidine in noncardiac surgery, incidence of
perioperative hypotension increased.34 On the contrary, in a
large cohort study, dexmedetomidine administration did not
inflict significant intraoperative hypotension.35 However, these
previous studies did not characterize cardiac function of the
participants. Therefore, further studies are needed to evaluate
the hemodynamic impact of dexmedetomidine administration
on not only patients with diastolic dysfunction but atherosclero-
sis, diabetes and other diseases correlated with abnormal
ratio of peak early diastolic transtricuspid inflow velocity to early dia
performance index.NO production.
The present study might have several limitations. First,
since this study was aimed to evaluate the net cardiac
6 | www.md-journal.comperformance during dexmedetomidine administration, we mini-
mally controlled the changes of blood pressure within clinically
acceptable ranges. We could not differentiate whether dexme-
detomidine directly impaired cardiac function or indirectly
depressed cardiac function by increase of afterload according
to the increase of blood pressure through this study. Thereby,
further study regarding the causal relationship between the 2
issues is needed. Second, in this study, dexmedetomidine was
used as an adjuvant agent to general anesthesia. Thus, we cannot
generalize the results of this study to assume the same results on
cardiac function in the case of dexmedetomidine as the sole
sedative. We applied general anesthesia using propofol and
remifentanil as the baseline anesthetics and monitored the depth
of anesthesia by BIS. There is controversy in the effects of
intravenous anesthetics on diastolic dysfunction. Propofol
administration has been shown to depress MV e0 and sub-
sequently lead to impaired diastolic function in patients with
normal cardiac function.36 However, in patients with preexist-
ing diastolic dysfunction, propofol administration did not
further aggravate diastolic function.37 Remifentanil did not
impair systolic or diastolic function in healthy patients.38
Further study is needed to evaluate the effects of dexmedeto-
midine as the sole sedative on cardiac function. Third, we could
not calculate pulmonary vascular resistance and pulmonary
wedge pressure, since we were unable to insert a pulmonary
artery catheter due to ethical issues. Therefore, we could not
confirm whether decrease in RV function was due to the
changes of pulmonary vascular resistance or to direct RV
depressant effects of dexmedetomidine. Further study will be
needed to assess the direct effects of dexmedetomidine on
pulmonary vasculature.
lic tricuspid annular velocity, RV MPI¼ right ventricular myocardialIn conclusion, intraoperative dexmedetomidine adminis-
tration during general anesthesia induced a sustained increase of
blood pressure and a deterioration of biventricular function
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Echocardiographic Variables of Left and Right Ventricle
Baseline 20 minutes 40 minutes 60 minutes Pgrouptime
LV E/e0 0.025
Dex 13.1 3.5 16.9 6.6, 16.5 4.9, 14.2 4.5,
Control 13.6 3.1 12.6 2.4 13.6 3.3 12.5 2.4
LV MPI < 0.001
Dex 0.76 0.19 0.94 0.25, 0.88 0.19, 0.85 0.21,
Control 0.76 0.19 0.73 0.18 0.76 0.16 0.73 0.13
MV e0, cm/s 0.039
Dex 4.4 1.2 3.4 1.3, 3.8 1.0, 4.1 1.2,
Control 4.6 1.0 4.5 0.6 4.5 0.8 4.7 0.6
MV s0, cm/s 0.003
Dex 5.7 0.8 5.1 0.9, 5.1 0.8, 5.4 0.8
Control 5.4 0.7 5.6 0.7 5.6 0.7 5.3 0.6
LV EF, % 0.015
Dex 68.6 3.6 58.7 5.9, 54.4 5.7, 62.7 8.1,
Control 66.5 5.7 67.3 3.3 66.0 5.7 66.8 3.3
LV FAC, % < 0.001
Dex 52.8 5.9 49.7 6.3, 47.5 6.9, 46.9 8.3,
Control 51.4 7.3 53.3 4.3 50.6 7.6 53.1 3.9
CO, L/min 0.001
Dex 4.6 0.7 3.3 0.7, 3.1 0.9, 3.3 0.6,
Control 4.2 0.6 4.4 1.0 4.3 0.7 4.2 0.9
RV E/e0 < 0.01
Dex 5.6 1.8 7.4 1.5, 7.2 1.4, 6.1 1.7
Control 6.3 1.8 6.4 1.4 6.2 1.4 6.1 0.7
RV MPI 0.028
Dex 0.5 0.1 0.6 0.2, 0.7 0.2, 0.6 0.1
Control 0.6 0.2 0.5 0.1 0.5 0.1 0.5 0.1
TV e0, cm/s 0.047
Dex 7.1 1.3 5.4 1.1, 4.8 1.3, 7.0 0.9
Control 7.1 0.7 6.6 1.7 6.7 1.0 7.2 0.8
TV s0, cm/s 0.041
Dex 13.0 0.8 8.5 3.0, 10.4 2.3, 12.9 1.1
Control 12.7 0.8 13.1 0.7 12.4 1.6 13.1 0.7
TAPSE, mm < 0.01
Dex 14.8 2.8 12.1 2.6, 12.4 2.7, 13.5 2.9
Control 14.6 2.1 14.2 1.7 14.5 2.2 14.6 2.2
Data are expressed as meanSD. 20¼ 20minutes after dexmedetomidine administration, 40¼ 40minutes after dexmedetomidine administration,
60¼ 60minutes after dexmedetomidine administration, Baseline¼ before administration of dexmedetomidine, Control¼ control group,
DEX¼ dexmedetomidine group, EF¼ ejection fraction, FAC¼ fractional area change, LV¼ left ventricle, MPI¼myocardial performance index,
MV e0 ¼ peak early diastolic mitral annular velocity, MV E¼ peak early diastolic transmitral inflow velocity, MV s0 ¼ peak systolic mitral annular
velocity, RV¼ right ventricle, TAPSE¼ tricuspid annular plane systolic excursion, TV e0 ¼ peak early diastolic tricuspid annular velocity, TV
E¼ peak early diastolic transtricuspid inflow velocity, TV s0 ¼ peak systolic tricuspid annular velocity.
P< 0.05 compared with Control group.
P< 0.01 compared with Control group.
P< 0.05 compared with Baseline.
Medicine  Volume 95, Number 6, February 2016 Dexmedetomidine and Diastolic Functionassessed by tissue Doppler imaging, in patients with diastolic
dysfunction. Since dexmedetomidine administration has the
possibility of aggravating cardiac function in patients with
diastolic dysfunction, we suggest careful consideration of its
use or a need for reducing its dosage when administrating
dexmedetomidine in patients with diastolic dysfunction.ACKNOWLEDGEMENTS
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